Related Experiment Video
Updated: Jan 29, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report
Cosimo Barbato1, Vito A Lasorsa1,2, Francesco Grimaldi3
1CEINGE Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
This case study details a myeloproliferative neoplasm (MPN) with a rare PDGFRB-CCDC88C fusion. Targeted tyrosine kinase inhibitor therapy achieved molecular remission, showcasing the importance of identifying atypical gene fusions in MPNs.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myeloproliferative neoplasms (MPNs) arise from hematopoietic stem cell transformation.
- A subset involves tyrosine kinase (TK) gene fusions, responsive to TK inhibitors.
- This case involves a rare myeloproliferative/myelodysplastic neoplasm in a young adult.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Data Reporting and Recording
Gene Therapy

